Eli Lilly and Company
7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors
Last updated:
Abstract:
A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I). ##STR00001##
Status:
Grant
Type:
Utility
Filling date:
8 Dec 2017
Issue date:
11 May 2021